For Julie Steenhuysen's latest contributions to The Japan Times, see below:
Leading drugmakers, including those who have launched pills and monoclonal antibodies for COVID-19, are having early discussions with researchers about how to target the disease.
The condition arises within three months of a COVID-19 infection and lasts at least two months.
Fauci has said U.S. states are facing tough choices in their efforts to balance the need to protect their citizens from infections and growing pandemic fatigue.
The surgery is among the first to demonstrate the feasibility of a pig-to-human heart transplant, a field made possible by new gene editing tools.
Disease experts say that rapidly shifting public health messaging in the face of a quickly mutating virus has bred confusion and mistrust over the benefit of boosters.
As the omicron variant gains momentum in Europe and the United States, scientists are rewriting their expectations for the COVID-19 pandemic next year.
Questions remain over whether the COVID-19 variant will evade vaccine protection and whether it will cause more serious illness.
Some experts fear the arrival of oral treatments for the coronavirus may further impede vaccination campaigns.
A fierce debate is expected around whether most Americans should get another shot rather than just those at high risk of severe illness.
Scientists remain focused on delta, now the dominant variant rising rapidly around the world, but they are tracking others to see what may one day take its place.
